Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane) - Agarwal, N; Chowdhury, S; Bjartell, A (J Clin Oncol, 2020)
et al.